Abstract: Methylopila sp. and use thereof in the selective resolution preparation of (S)-?-ethyl-2-oxo-1-pyrrolidineacetate. Methylopila sp. that produces enzymes is subjected to cell immobilization, and is then applied to the biological resolution of a racemate (R,S)-?-ethyl-2-oxo-1-pyrrolidineacetic acid ethyl ester to prepare high optically pure (S)-?-ethyl-2-oxo-1-pyrrolidineacetic acid ethyl ester, which is further subjected to a hydrolysis reaction to obtain (S)-?-ethyl-2-oxo-1-pyrrolidineacetate. The present invention achieves a high conversion yield up to 50.0% or more, a good stereoselectivity, and an enantiomeric excess value e.e.s (%) of (S)-?-ethyl-2-oxo-1-pyrrolidineacetic acid ethyl ester not less than 99.5; the catalytic efficiency is high; the concentration of the racemic substrate in the resolution reaction is up to 500 g/L, the reaction time does not exceed 15 h, the number of reuse times of the immobilized cells is not lower than 35.

Abstract: The invention comprises a novel composite seed layer with lattice-matched crystalline structure so that an excellent epitaxial growth of magnetic pinning layer along its FCC (111) orientation can be achieved, resulting in a significant enhancement of PMA for perpendicular spin-transfer-torque magnetic-random-access memory (pSTT-MRAM) using perpendicular magnetoresistive elements as basic memory cells which potentially replace the conventional semiconductor memory used in electronic chips, especially mobile chips for power saving and non-volatility.

Abstract: An intelligent temperature adjustment control circuit includes a first, resistance sampling circuit, a second resistance sampling circuit, a current sampling circuit, a voltage sampling circuit and a thermocouple sensor, respectively connected to a heating wire. The thermocouple sensor is connected in turn with an analog-to-digital converter and a signal isolation driving circuit to collect real-time temperature data of the heating wire and then transmit it to a main control unit after being processed. The main control unit is configured to determine the received initial resistance value, the real-time resistance value, the real-time current value, the real-time voltage value and the voltage digital signal, and then send a control signal to a main driving circuit according to a judgment result of the received initial resistance value, the real-time resistance value, the real-time current value, the real-time voltage value and the voltage digital signal, that have been determined.

Abstract: The present disclosure relates to a method and an apparatus for representation of a sparse matrix in a neural network. In some embodiments, an exemplary operation unit includes a buffer for storing a representation of a sparse matrix in a neural network, a sparse engine communicatively coupled with the buffer, and a processing array communicatively coupled with the sparse engine. The sparse engine includes circuitry to: read the representation of the sparse matrix from the buffer, the representation comprising a first level bitmap, a second level bitmap, and an element array; decompress the first level bitmap to determine whether a block of the sparse matrix comprises a non-zero element; and in response to the block comprising a non-zero element, decompress the second level bitmap using the element array to obtain the block of the sparse matrix. The processing array includes circuitry to execute the neural network with the sparse matrix.

Abstract: Methods and systems for digitally reconstructing a patient tissue sample are described herein. In one embodiment, the method may include projecting a first structured light pattern onto the patient tissue sample, receiving a first reflection of the first structured light pattern from the patient tissue sample, and reconstructing the patient tissue sample based on the first reflection and the projected first structured light pattern. In another embodiment, the system may include a projector adapted or configured to project the first structured light onto the patient tissue sample, a charge-coupled device (CCD) adapted or configured to receive the first reflection from the patient tissue sample, and a reconstruction device adapted or configured to reconstruct the patient tissue sample based on the first reflection and the projected first structured light pattern.

Abstract: The present invention relates to a wound management composition consisting of full spectrum blend of active cannabinoids and at least one hemostatic agent including astringent-class hemostats, active-class hemostats, and active-mechanical-class hemostats. Further, the composition may also include at least chemical penetration enhancer that amplifies the absorption of cannabinoids, at least one local drug to prolong the pharmacologically active time of cannabinoids, at least one antibacterial agent, and at least one antifungal agent. Methods of delivery of the wound management composition and kits are also disclosed.

Abstract: This description provides an autonomous or semi-autonomous excavation vehicle that is capable of navigating through a dig site and carrying out an excavation routine using a system of sensors physically mounted to the excavation vehicle. The sensors collects any one or more of spatial, imaging, measurement, and location data representing the status of the excavation vehicle and its surrounding environment. Based on the collected data, the excavation vehicle executes instructions to carry out an excavation routine. The excavation vehicle is also able to carry out numerous other tasks, such as checking the volume of excavated earth in an excavation tool, and helping prepare a digital terrain model of the site as part of a process for creating the excavation routine.

Abstract: A perfluoropolymer hollow fiber composite membrane preparation method includes the steps of (A) preparing a supporting layer of the perfluoropolymer hollow fiber composite membrane, (B) preparing a membrane casting solution, which includes obtaining a mixed solution by mixing a perfluoropolymer water dispersion emulsion, a spinning carrier and solvent, and defoaming the mixed solution at vacuum and a constant temperature, (C) preparing a nascent hollow fiber composite membrane, which includes compositing by uniformly coating the membrane casting solution on an outer surface of the supporting layer through an annular spinneret using chemical fiber concentric circle composite spinning technology, putting the supporting layer after compositing into a coagulant, solidifying and forming, and (D) drying after putting the nascent hollow fiber composite membrane to a hot air box, cleaning, sintering, and performing heat preservation.

Abstract: The present invention relates to novel compounds of formula (I), wherein R1, R2, R3, R4, R5, R6 and R7 are as described herein, and their pharmaceutically acceptable salt, enantiomer or diastereomer thereof, and compositions including the compounds and methods of using the compounds.

Abstract: The present application provides a lithium niobate having a p-type nanowire region or an n-type nanowire region and a method for preparing the same. The method includes heating and then cooling a multi-domain lithium niobate crystal to confine hydrogen ions of the multi-domain lithium niobate crystal in domain wall regions; and poling the multi-domain lithium niobate crystal that has been heated by applying a voltage, to reverse a direction of polarization of one or more domains of the multi-domain lithium niobate crystal. The lithium niobate includes a lithium niobate crystal and a p-type nanowire region or an n-type nanowire region located in the lithium niobate crystal and adjacent to a surface of the lithium niobate crystal. The present application also provides a method for converting the charge carrier type of the lithium niobate nanowire region.

Abstract: Provided by the present invention are an antibody against human TIM-3 or an antigen-binding fragment thereof, and further provided are a nucleic acid molecule encoding the antibody, an expression vector for expressing the antibody and a host cell, and a method for producing the antibody. Further provided by the present invention are a pharmaceutical composition comprising the antibody or an antigen-binding fragment of the antibody, and an application of the pharmaceutical composition in the preparation of a medicine, the medicine is used for preventing and/or treating various diseases (including tumors, infectious diseases and autoimmune diseases).

Abstract: An example of a biotin-streptavidin cleavage composition includes a formamide reagent and a salt buffer. The formamide reagent is present in the biotin-streptavidin cleavage composition in an amount ranging from about 10% to about 50%, based on a total volume of the biotin-streptavidin cleavage composition. The salt buffer makes up the balance of the biotin-streptavidin cleavage composition. In some examples, the biotin-streptavidin cleavage composition is used to cleave library fragments from a solid support. In other examples, other mechanisms are used to cleave library fragments from a solid support.

Abstract: Approaches in accordance with various embodiments can reduce scheduling delays due to concurrent processing requests, as may involve VSyncs in multi-streaming systems. The software synchronization signals can be staggered relative to each other by offsetting an initial synchronization signal. These software synchronization signals can be readjusted over time such that each synchronization signal maintains the same relative offset, as may be with respect to other applications or containers.

Abstract: The present disclosure provides binding proteins (e.g., antibodies or antigen binding fragments thereof) that specifically bind to Klebsiella pneumoniae O2 and induce opsonophagocytic killing of Klebsiella (e.g., Klebsiella pneumoniae) and/or protects mice from a lethal Klebsiella challenge. The present disclosure also provides methods of reducing Klebsiella (e.g., Klebsiella pneumoniae) or treating or preventing Klebsiella (e.g., Klebsiella pneumoniae) infection in a subject comprising administering the Klebsiella pneumoniae O2 binding proteins, (e.g., antibodies or antigen-binding fragments thereof) to the subject.

Abstract: Disclosed is a motor rotor structure including a rotor core. A plurality of radial slots each are in the rotor core along a circumferential direction, and a first flux barrier slot is provided between every two adjacent radial slots. Two kinds of permanent magnets having different coercivities mounted in each radial slot. The two kinds of permanent magnets having different coercivities are distributed along a radial direction of the rotor core. The two kinds of permanent magnets having different coercivities are both magnetized along a tangential direction of the rotor core. A second flux barrier slot is provided between the two kinds of permanent magnets having different coercivities.

Abstract: Embodiments of the present invention relate to methods, systems, and computer program products for distributed transaction management. In a method, a first transaction is performed, where both a first data in a first application system and a second data in a second application system are to be accessed in the first transaction. A second transaction is identified in response to a determination that the second data in the second application system fails to be accessed in the first transaction, the first data in the first application system being accessed in the second transaction during performing the first transaction. A value of the first data is determined based on status of the first transaction and status of the second transaction.

Abstract: Disclosed are compounds which inhibit Pin1 activity, methods of making the compounds, pharmaceutical compositions containing the compounds, and methods of using the compounds to treat diseases or disorders characterized or mediated by dysregulated Pin1 activity.

Abstract: The disclosure of the present invention provides a method for searching blockchain data, comprising: A. receiving a webpage read request sent by a search engine via a hypertext transfer protocol (HTTP) interface, the webpage read request including a first uniform resource locator address and smart contract supporting information; B. obtaining first blockchain data at the first uniform resource locator address; C. obtaining smart contract information associated with the first blockchain data, wherein the smart contract information includes a smart contract address information; D. determining whether there is at least one second uniform resource locator address, wherein second blockchain data at the at least one second uniform resource locator address is associated with the first blockchain data; E.

Abstract: A triptolide derivative, a preparation method therefor, and a method for use thereof are described. The triptolide derivative has the structure as shown in general formula I, and the definition of each substituent is as described in the description and claims. The triptolide derivative has improved immunosuppressive activity and anti-tumor activity, low toxicity and high safety, thus having good development and application prospects.